These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 28366429)

  • 21. California cracks down on stem cell cowboys.
    DeFrancesco L
    Nat Biotechnol; 2017 Dec; 35(12):1119. PubMed ID: 29220025
    [No Abstract]   [Full Text] [Related]  

  • 22. To market, to market. The nuts and bolts of prescription drug approval.
    Peterson AM
    Adv Nurse Pract; 2001 Apr; 9(4):87-90. PubMed ID: 12420443
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmaceuticals and medical devices: FDA oversight.
    Berry MD
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-123. PubMed ID: 24482893
    [No Abstract]   [Full Text] [Related]  

  • 24. Solving lymphoma's stem-cell problem.
    Arney K
    Nature; 2018 Nov; 563(7731):S48-S49. PubMed ID: 30429564
    [No Abstract]   [Full Text] [Related]  

  • 25. Stem cells in Texas: Cowboy culture.
    Cyranoski D
    Nature; 2013 Feb; 494(7436):166-8. PubMed ID: 23407522
    [No Abstract]   [Full Text] [Related]  

  • 26. Marketing drugs too early in testing.
    Begg CB; Brawley O; Califf RM; Demets DL; Ellenberg SS; Kaplan RS
    Science; 2006 Apr; 312(5771):195. PubMed ID: 16614197
    [No Abstract]   [Full Text] [Related]  

  • 27. Drug marketing exclusivity under United States and European Union law.
    Junod V
    Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
    [No Abstract]   [Full Text] [Related]  

  • 28. Changes at FDA may speed drug approval process and increase off-label use.
    Reh M
    J Natl Cancer Inst; 1998 Jun; 90(11):805-7. PubMed ID: 9625166
    [No Abstract]   [Full Text] [Related]  

  • 29. Challenges in the Regulation of Autologous Stem Cell Interventions in the United States.
    Sipp D
    Perspect Biol Med; 2018; 61(1):25-41. PubMed ID: 29805146
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulatory aspects of drug approval for macular degeneration.
    Gryziewicz L
    Adv Drug Deliv Rev; 2005 Dec; 57(14):2092-8. PubMed ID: 16316706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progress and deficiencies in the registration of clinical trials.
    Wood AJ
    N Engl J Med; 2009 Feb; 360(8):824-30. PubMed ID: 19228628
    [No Abstract]   [Full Text] [Related]  

  • 32. The problem of new uses.
    Eisenberg RS
    Yale J Health Policy Law Ethics; 2005; 5(2):717-39. PubMed ID: 16052897
    [No Abstract]   [Full Text] [Related]  

  • 33. Stem-cell-derived products: an FDA update.
    Moos M
    Trends Pharmacol Sci; 2008 Dec; 29(12):591-3. PubMed ID: 18937983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stem cell transplantation in India: tall claims, questionable ethics.
    Pandya SK
    Indian J Med Ethics; 2008; 5(1):15-7. PubMed ID: 18630246
    [No Abstract]   [Full Text] [Related]  

  • 35. Lessons for reviewing clinical trials using induced pluripotent stem cells: examining the case of a first-in-human trial for age-related macular degeneration.
    Takashima K; Inoue Y; Tashiro S; Muto K
    Regen Med; 2018 Mar; 13(2):123-128. PubMed ID: 29210321
    [No Abstract]   [Full Text] [Related]  

  • 36. Recasting cancer trials.
    Nat Biotechnol; 2012 Jul; 30(7):567. PubMed ID: 22781659
    [No Abstract]   [Full Text] [Related]  

  • 37. Transforming Drug Development in Heart Failure: Navigating the Regulatory Crossroads.
    Vaduganathan M; Butler J; Gheorghiade M
    Circ Heart Fail; 2016 Oct; 9(10):. PubMed ID: 27707750
    [No Abstract]   [Full Text] [Related]  

  • 38. Moment of reckoning.
    Wadman M
    Nature; 2007 Apr; 446(7138):844-5. PubMed ID: 17443154
    [No Abstract]   [Full Text] [Related]  

  • 39. Stem cells in aesthetic dermatology: bioethical and professional obligations.
    Wang JV; Schoenberg E; Rohrer T; Zachary CB; Saedi N
    Arch Dermatol Res; 2019 Dec; 311(10):833-835. PubMed ID: 31321506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Off the grid.
    Nat Biotechnol; 2016 Sep; 34(9):891. PubMed ID: 27606441
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.